within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD13_MetforminAndAlogliptin;

model MetforminAndAlogliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and alogliptin is a fixed-dose combination of two antihyperglycemic agents used in the treatment of type 2 diabetes mellitus. Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity, while alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion and decrease glucagon levels. This combination is approved for use in adults with type 2 diabetes mellitus when diet and exercise do not provide adequate glycemic control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for usual adult population under typical dosing after oral administration; no published model specifically for the metformin and alogliptin combination, so parameters are based on combination of published values for individual components.</p><h4>References</h4><ol><li><p>Karim, A, et al., &amp; Mekki, Q (2010). Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. <i>International journal of clinical pharmacology and therapeutics</i> 48(1) 46–58. DOI:<a href=\"https://doi.org/10.5414/cpp48046\">10.5414/cpp48046</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20040339/\">https://pubmed.ncbi.nlm.nih.gov/20040339</a></p></li><li><p>Scott, LJ (2010). Alogliptin: a review of its use in the management of type 2 diabetes mellitus. <i>Drugs</i> 70(15) 2051–2072. DOI:<a href=\"https://doi.org/10.2165/11205080-000000000-00000\">10.2165/11205080-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20883057/\">https://pubmed.ncbi.nlm.nih.gov/20883057</a></p></li><li><p>Janardhan, S, &amp; Sastry, GN (2014). Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment. <i>Current drug targets</i> 15(6) 600–621. DOI:<a href=\"https://doi.org/10.2174/1389450115666140311102638\">10.2174/1389450115666140311102638</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24611684/\">https://pubmed.ncbi.nlm.nih.gov/24611684</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndAlogliptin;
